Use your browser's back button to choose another title or click here for a New Search.



How to Get the Article

 Email CTN Library (free)

PubMed Central (free)

Journal subscriber access

 

 

Bookmark and Share

 

 

CTN-0050
Primary
Outcomes

 

 

Long-Term Outcomes After Randomization to Buprenorphine/Naloxone Versus Methadone in a Multi-Site Trial.

Addiction 2016;111(4):695-705. [doi: 10.1111/add.13238]

Yih-Ing Hser, PhD (University of California, Los Angeles (UCLA), PR Node), Elizabeth Evans, MA (UCLA, PR Node), David Huang (UCLA, PR Node), Roger D. Weiss, MD (UCLA, PR Node), Andrew J. Saxon, MD (Veterans Affairs Puget Sound Haelth Care System, PN Node), Kathleen M. Carroll, PhD (Yale University, NEC Node), George E. Woody, MD (University of Pennsylvania School of Medicine, DV Node), David S. Liu, MD (Center for the Clinical Trials Network, NIDA), Paul G. Wakim, PhD (Center for the Clinical Trials Network, NIDA), Abigail G. Matthews, PhD (Data & Statistics Center, EMMES), Mary A. Hatch-Maillette, PhD (Alcohol & Drug Abuse Institute, University of WA, PN Node), Eve Jelstrom, MBA (Clinical Coordinating Center, EMMES), Katharina Wiest, PhD (University of California, Los Angeles, PR Node), Paul McLaughlin, MA (Hartford Dispensary, NEC Node), Walter Ling, MD (UCLA, PR Node).

This is the Primary Outcomes Article for CTN-0050. This study, a long-term follow-up of patients from the NIDA Clinical Trials Network's Starting Treatment with Agonist Replacement Therapy (START, CTN-0027), aimed to compare long-term outcomes among participants randomized to buprenorphine (BUP) or methadone (MET), including mortality, opioid use status during/after 60-month follow-up, treatment participation status and retention over the 60-month period, and the effects of each type of opioid replacement treatment (BUP or MET) on level of opioid use over the 60-month period. Follow-up was conducted in 2011-2014 on 1,080 opioid-dependent participants entering 7 opioid treatment programs in the US between 2006-2009 and randomized (within each program) to receive open-label buprenorphine/naloxone or methadone for up to 24 weeks; 795 participants completed in-person interviews (~74% follow-up interview rate) covering, on average, 4.5 years.

Analysis revealed no difference in mortality between the two randomized conditions, with 23 (3.6%) of 630 participants randomized to buprenorphine having died, versus 26 (5.8%) of 450 randomized to methadone. Opioid use at follow-up was higher among participants randomized to buprenorphine relative to methadone (42.8% vs. 31.7% positive opioid urine specimens; 5.8 days vs. 4.4 days of past 30-day heroin use). Opioid use over the follow-up period by randomization condition was also significant, mostly due to less treatment participant among participants randomized to buprenorphine than methadone. Less opioid use was associated with both buprenorphine and methadone treatment (relative to no treatment); no difference was found between the two treatments. Individuals who are white or used cocaine at baseline responded better to methadone than to buprenorphine.

Conclusions: There are few differences in long-term outcomes between buprenorphine and methadone treatment for opioid dependence, and treatment with each medication is associated with a strong reduction in opioid use. This study, the first to follow opioid dependent individuals randomized to two opioid maintenance treatments prospectively over 5 or more years, is instructive about longer term outcomes and poses a challenge to the field to enhance retention in the opioid maintenance treatment. Many individuals with opioid use disorder cycle in and out of maintenance treatment, and this study confirms they show better outcomes when retained in that treatment instead. Efforts are needed, especially in the context of the current opioid epidemic, to improve both BUP and MET treatment retention. (Article (Peer-Reviewed), PDF, English, 2016)

Keywords: Buprenorphine | Buprenorphine/Naloxone | Cocaine | CTN primary outcomes | Heroin | Methadone maintenance | Pharmacological therapy | Prescription-type opiates | Retention - Treatment | Suboxone | Addiction (journal)

Document No: 1180, PMID: 26599131, PMCID: PMC4801718.

Submitted by CTN Dissemination Librarians, 11/30/2015.

AUTHORS SEARCH LINK
Carroll, Kathleen M. search mail
Evans, Elizabeth search mail
Hatch-Maillette, Mary A. search mail
Hser, Yih-Ing search mail
Huang, David search
Jelstrom, Eve search mail
Ling, Walter search mail
Liu, David S. search mail
Matthews, Abigail G. search mail
McLaughlin, Paul search mail
Saxon, Andrew J. search mail
Wakim, Paul G. search mail
Weiss, Roger D. search mail
Wiest, Katharina search mail
Woody, George E. search mail
PROTOCOLS
NIDA-CTN-0050 search www
PARTICIPATING NODES
Pacific Region (Lead) search www
Delaware Valley search www
New England Consortium search www
Pacific Northwest search www
Western States search www

Supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute.
The materials on this site have neither been created nor reviewed by NIDA.
Updated 5/2017 -- http://ctndisseminationlibrary.org/display/1180.htm
info@ctndisseminationlibrary.org